Clinical trial · Observational
Pancreatic Cancer Early Detection Registry
NCT05519930CI-TRIAL-00081518completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Identify individuals who are at moderate and high risk or predisposed to developing pancreatic cancer with a familial history in which data collected from this study will be used to identify clinical factors associated with early detection of pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| hereditary high risk pancreatic cancer | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Evaluation of imaging for early detection of pancreatic cancer in the high-risk group as defined by inclusion criteria to determine their level of risk and perform surveillance accordingly.
- timeFrame
- Eight years
- description
- Imaging includes CT/MRI abdomen with and without contrast using the pancreatic protocol, screening for solid pancreatic lesions, atypical cysts and IPMN, pancreatic duct dilatation, pancreas divisum.
- measure
- Evaluation of blood samples for early detection of pancreatic cancer in the high-risk group as defined by inclusion criteria to determine their level of risk and perform surveillance accordingly.
- timeFrame
- Eight years
- measure
- Evaluation of endoscopic ultrasound for early detection of pancreatic cancer in the high-risk group as defined by inclusion criteria to determine their level of risk and perform surveillance accordingly
- timeFrame
- Eight years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
1. Eligible subjects must be ≥ 18 years of age
2. Meet one of the following criteria:
* All affected on the same side of the family (maternal/paternal) unless otherwise specified FDR = first degree relative (parent, sibling, child)
* SDR = second degree relative (e.g., aunt, uncle, grandparent, half-sibling, niece and nephew)
* TDR = third degree relative (e.g., cousin, half-aunt or half-uncle)
* 1 FDR with pancreatic cancer \< age 55
-≥2 FDR, SDR or TDR with pancreatic cancer at any age
* Genetic syndrome with pancreatic cancer
* FDR or SDR with pancreatic cancer at any age and Ashkenazi ancestry
* FDR or SDR with pancreatic cancer at any age and:
* 1 relative with ovarian cancer at any age or
* 1 relative with breast cancer ≤50 or
* 2 relatives with breast, pancreatic or prostate cancer (Gleason score ≥7) at any age
* Family history of melanoma OR
* Has previously had genetic testing and has been determined to have a pathogenic gene variant.
* FDR with a pathogenic gene variant
Exclusion Criteria:
1. Prior treatment of pancreatic cancer including radiation therapy, systemic therapy and/or surgery.
2. Current treatment of pancreatic cancer including radiation therapy, systemic therapy and/or surgery.References
Publications (0)
Data not yet available
No reference posted for this study.